Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finotonlimab + SCT510 vs Sorafenib in Advanced HCC
NCT04560894Phase 3Active, not recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Nov 2020
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of finotonlimab in hepatocellular carcinoma (HCC), sponsored by Sinocelltech Group Limited. Started Nov 2020; status: active, not recruiting.
02
Drugs
finotonlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04560894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560894.